{"id":389122,"date":"2023-12-05T00:00:00","date_gmt":"2023-12-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0011-2023-biopharma-ovarian-cancer-disease-landscape-forecast-g7-2023\/"},"modified":"2026-04-25T23:14:18","modified_gmt":"2026-04-25T23:14:18","slug":"dlsfon0011-2023-biopharma-ovarian-cancer-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0011-2023-biopharma-ovarian-cancer-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Ovarian Cancer | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca \/ Merck &#038; Co.), Zejula (GlaxoSmithKline), and Rubraca (Clovis Oncology). In November 2022, Elahere (ImmunoGen) entered the U.S. market as the first antibody-drug conjugate for patients with folate receptor alpha (FR\u03b1)-positive tumors. The late-phase pipeline for ovarian cancer is rapidly evolving. Novel drugs with a variety of mechanisms of action are set to launch for ovarian cancer and further diversify treatment options.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul>\n<li>What is the size of the clinically and commercially relevant drug-treatable ovarian cancer population, and how will drug-treatment rates change over time?<\/li>\n<li>What is the current treatment landscape for ovarian cancer? What are interviewed experts\u2019 insights on current therapies?<\/li>\n<li>What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?<\/li>\n<li>What are the main drivers of and constraints in the treatment of ovarian cancer, and how will this market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389122","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ovarian-cancer","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389122\/revisions"}],"predecessor-version":[{"id":576028,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389122\/revisions\/576028"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}